Posted by admin | Posted in General | Posted on 06-08-2011
Tags: Baldness Propecia, Breast Milk, Cancer Drug, Cipla, Crown Area, Drug, Finasteride, Generic Brands, Generic Versions, Hair, Hair Loss Problem, Hairline, loss, Male Baldness, Male Pattern Baldness, Milligram, Offshoot, Propecia, Propecia Drug, Propecia Finasteride, Prostate Cancer, Ranbaxy, Sizefitsall, Stimulating Hair Growth, Unborn Babies
Holding the approval of FDA in 1997 for the treatment of men baldness, Propecia was known before as a prostate cancer drug. With just about 30-65% of the man taking it orally show good result in hair improvement, the effectiveness of this drug is still a question for those with hair loss problem. It is most effective in the crown area, although Propecia has also proven to be effective in re stimulating hair growth around the hairline. In 2006, Merck’s patent on Propecia expired, allowing other companies such as Cipla and Ranbaxy to market generic versions of the drug with no infringement repercussions.
Some of the offshoot, generic brands of Propecia (Finasteride) are Finax Finasteride, Fincar Finasteride, and Prosteride. After the patent expired, these medications were sold around the world in 5 milligram doses.
The fact that the patent has expired has opened up doors for other drug companies other than Merck, to market finasteride in 5 milligram tablets as a treatment for male pattern baldness.
Of course, with or without a patent, Propecia and its duplicates do have side effects. The active ingredient in Propecia is of course Finasteride. Finasteride has been proven to cause birth defects in women with unborn babies, even if not ingested. All a woman has to do to get finasteride into her system is to handle to the crumbs from crushed tablets, and it gets into the blood. It can also be transferred through breast milk, and finasteride certainly is not healthy for infants.
